Ensovibep clinical trials
Also written MP0420.
How each study uses ensovibep is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Molecular Partners AG (2) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Bamlanivimab (1) · Sotrovimab (1) · Cilgavimab and tixagevimab drug combination (1) · Lufotrelvir (1)
Studies
Open first, then newest update. How each study uses ensovibep is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19TerminatedPhase 2/3Novartis PharmaceuticalsNCT04828161Written as ensovibep
- MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780463Written as MP0420
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as MP0420
- Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)TerminatedPhase 1Molecular Partners AGNCT04870164Written as Ensovibep
- Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 PatientsCompletedPhase 2Molecular Partners AGNCT04834856Written as ensovibep
Codes
What other systems call ensovibep · ClinicalTrials.gg INT001594
- MeSH (NLM) C000715987ensovibepOne source NLM
- UNII (FDA) PV6AA88RDUENSOVIBEPConfirmed FDA, NLM
- NCI Thesaurus C179065EnsovibepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000715987 | ensovibep | One source NLM |
| UNII (FDA) | PV6AA88RDU | ENSOVIBEP | Confirmed FDA, NLM |
| NCI Thesaurus | C179065 | Ensovibep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.